Eliem Q1 net loss $13.2M; ETX-810 fails DPNP trial; ETX-155 data inconclusive; LSRP data Q3

Climb Bio, Inc.

2023-Q1 EPS reported -$0.50

Net loss of $13.2M in Q1 2022 vs $18.6M in Q1 2021; cash $149.9M, funded through at least 2023.
ETX-810 Phase 2a in diabetic peripheral neuropathic pain failed primary endpoint; LSRP trial fully enrolled, topline data Q3 2022.
ETX-155 Phase 1b photosensitive epilepsy interim results inconclusive due to lower exposure; Phase 2a MDD/PMD enrollment delayed pending root cause.
Preclinical Kv7.2/3 channel opener on track for IND-enabling studies in 2022; early anxiolytic program for GAD continues.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.